CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.58
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$264.05

01 Aug
2025

-6.850

OPEN

$269.10

-2.53%

HIGH

$269.74

1,173,472

LOW

$263.18

TARGET
$318.043 20.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 1009.3 xxx
DPS (cps) 456.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 26.2 xxx
Dividend Yield 1.7% xxx
Div Pay Ratio(%) 45.3% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.38%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.55

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx834.7
DPS All xxxxxxxxxxxxxxx397.4
Sales/Revenue xxxxxxxxxxxxxxx22,417.6 M
Book Value Per Share xxxxxxxxxxxxxxx5,379.9
Net Operating Cash Flow xxxxxxxxxxxxxxx4,218.0 M
Net Profit Margin xxxxxxxxxxxxxxx17.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx16.22 %
Return on Invested Capital xxxxxxxxxxxxxxx9.68 %
Return on Assets xxxxxxxxxxxxxxx7.24 %
Return on Equity xxxxxxxxxxxxxxx16.22 %
Return on Total Capital xxxxxxxxxxxxxxx12.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,103.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1,413 M
Long Term Debt xxxxxxxxxxxxxxx16,829 M
Total Debt xxxxxxxxxxxxxxx18,242 M
Goodwill - Gross xxxxxxxxxxxxxxx12,097 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,481 M
Price To Book Value xxxxxxxxxxxxxxx5.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1,919.8 M
Capex % of Sales xxxxxxxxxxxxxxx8.56 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,505 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5,263 M
Research & Development xxxxxxxxxxxxxxx2,182 M
Investments - Total xxxxxxxxxxxxxxx244 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

20/06/2025

1

Buy

$310.00

17.40%

After reviewing CSL's model, Ord Minnett has concluded growth in high-margin specialty products can help in offsetting narrowing margins in the immunoglobulin and albumin businesses.

This view was strengthened with this week's FDA approval for the Andembry injection, which the broker expects will help the company return to solid growth in specialty products. The analyst is now forecasting a compounded annual revenue growth rate of 5% for the specialty division over FY26-28.

No changes to group EPS estimates. Buy with unchanged target of $310.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

12/02/2025

3

Market Weight

$250.00

-5.32%

CSL beat forecasts for Behring and Vifor in the 1H25 result but Seqirus' performance missed, Wilsons notes. The company reaffirmed FY25 net profit guidance of US$3.2-$3.3bn and gross margin increase of over 100bps for Behring.

The broker raised FY25 net profit estimate by 0.8% to US$3.2bn, noting it is at the lower end of CSL guidance. The analyst marginally raised FY25 EPS forecast but lowered FY26 by -4.4%, with the downgrade centred on Seqirus.

The broker's valuation is based on DCF which in USD terms is down -18%, but translates to -14% in AUD terms. New target price is $250.

Market Weight rating maintained with the broker reiterating CSL remains relatively expensive compared to global biopharma.

FORECAST
Wilsons forecasts a full year FY25 dividend of 448.43 cents and EPS of 1022.27 cents.
Wilsons forecasts a full year FY26 dividend of 488.79 cents and EPS of 1089.53 cents.
Access Extra Coverage Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudi’s View: Taking Stock Ahead Of August

Jul 30 2025 - Rudi's View
2
Next Week At A Glance – 28 July-1 Aug 2025

Jul 25 2025 - Weekly Reports
3
Rudi’s View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

Jul 24 2025 - Rudi's View
4
Rudi’s View: Extreme Bifurcation Ahead Of August

Jul 23 2025 - Rudi's View
5
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
2
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
3
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
4
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
5
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
6
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
7
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
8
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
9
CSL Shares Breaking Free

Jul 23 2024 - Technicals
10
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps